|
| | IKK Inhibitor III, BMS-345541 Basic information |
| Product Name: | IKK Inhibitor III, BMS-345541 | | Synonyms: | IKK Inhibitor III, BMS-345541;BMS 345541 (free base);BMS345541 (free base);BMS-345541 (free base);N-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine;1,2-Ethanediamine, N1-(1,8-dimethylimidazo[1,2-a]quinoxalin-4-yl)-;N-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)-1,2-ethanediamine BMS345541;N1-(1,8-Dimethylimidazo[1,2-a]quinoxalin-4-yl)ethane-1,2-diamine | | CAS: | 445430-58-0 | | MF: | C14H17N5 | | MW: | 255.32 | | EINECS: | | | Product Categories: | IκB/IKK;Inhibitors;A cell-permeable quinoxaline compound that displays anti-inflammatory properties.;IKK | | Mol File: | 445430-58-0.mol |  |
| | IKK Inhibitor III, BMS-345541 Chemical Properties |
| Boiling point | 449.5±45.0 °C(Predicted) | | density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | insoluble in H2O; ≥70 mg/mL in DMSO; ≥2.49 mg/mL in EtOH with gentle warming and ultrasonic | | form | Powder | | pka | 9.02±0.10(Predicted) | | CAS DataBase Reference | 445430-58-0 |
| | IKK Inhibitor III, BMS-345541 Usage And Synthesis |
| Characteristics | Allosteric IKK inhibitors have anti-inflammatory activity. | | Uses | BMS-345541 is a potent, selective, and allosteric site-binding inhibitor of IKK β (IKK-2) and shows 10 times greater selectivity over IKK α (IKK-1). BMS-345541 also inhibits cellular Iκβα phosphorylation and has some anti-inflammatory properties. | | Definition | ChEBI: N'-(1,8-dimethyl-4-imidazo[1,2-a]quinoxalinyl)ethane-1,2-diamine is a quinoxaline derivative. | | Biological Activity | BMS-345541 highly selectively inhibits the catalytic subunits of IKK-2 and IKK-1 with IC50s of 0.3 μM and 4 μM, respectively. | | in vitro | BMS-34554 (5 μM) induces time-dependent dephosphorylation of IκBα and p65. Treatment of T-ALL cells with BMS-34554 resulted in nuclear translocation of FOXO3a, including control of the expression level of the p21CIP1 gene. In human umbilical vein endothelial cells, BMS-345541 inhibits TNFα-induced expression of ICAM-1 and VCAM-1 with IC50 of 5 μM. | | in vivo | BMS-345541 (100 mg/kg) reduced the cumulative arthritis damage score from 4.4 to 0, along with low-grade degradation and inflammation of the tibiotarsal joint, synovial hyperplasia, bone resorption, and severity of cartilage erosion. There was no apparent damage to the joints of the animals, which was indistinguishable from the histological phenotype observed in those from age-matched, disease-free control animals. BMS-345541 dose-dependently inhibited IL-1β signaling, with animals in the 100 mg/kg dose group exhibiting levels consistent with disease-free control animals. | | target | | Target | Value | IKK2
(Cell-free assay) | 0.3 μM | IKK1
(Cell-free assay) | 4 μM |
|
| | IKK Inhibitor III, BMS-345541 Preparation Products And Raw materials |
|
